[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"her2-status-in-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:her2-status-in-breast-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100651170","updates-and-insights-on-her2-in-breast-cancer-in-sohag-governorate-100651170",false,"NCT07758127","Updates and Insights on HER2 in Breast Cancer in Sohag Governorate","Updates and Insights on Human Epidermal Growth Factor Receptor 2 (HER2) in Breast Cancer in Sohag Governorate","HER2","Inclusion Criteria:\n\n* Breast cancer cases diagnosed during 2025 and 2026.\n* Cases with available HER2 immunohistochemical results.\n* Cases with sufficient tissue material for evaluation.\n* Cases with complete clinical and follow-up data.\n* Cases that were accessible for pathologic review\n\nExclusion Criteria:\n\n* Cases with insufficient, destroyed, necrotic, or unavailable tissue blocks.\n* Cases with incomplete clinical information.\n* Cases lacking adequate immunohistochemical assessment.\n* Cases outside the study period","FEMALE","26 Years","85 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.\n* To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes\n* To access interobserval agreement in HER2 score interpretation",[26],"HER2 Status in Breast Cancer",[15],"NOT_YET_RECRUITING","2026-08-10",{"date":31,"type":32},"2026-08-12","ACTUAL",{"date":34,"type":22},"2026-09",{"date":36,"type":22},"2027-12",{"name":38,"class":39},"Sohag University","OTHER"]